✦ LIBER ✦

PCN2I A PHARMACOECONOMIC MODEL OF THE COST-EFFECTIVENESS OF GEFITINIB (“IRESSA”) COMPARED WITH BEST SUPPORTIVE CARE (BSC) IN THIRD-LINE TREATMENT OF PATIENTS WITH REFRACTORY ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) IN THE UK

✍ Scribed by AE Ratcliffe; SM Beard; S Wolowacz

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Vinorelbine (VNR) plus best supportive c

✍ Gridelli, C; Ianniello, GP; Maiorino, L; Brancaccio, L; Cigolari, S; Bilancia, D 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 229 KB

O-11 Estimating the financial cost of su

✍ West, Peter; Maslove, Lisa; Gower, Nicole; Stephens, Richard J. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 189 KB

CN3 PHARMACOECONOMIC (PE) ANALYSIS OF TH

✍ M Pompen; A Novak; P Postmus; M Gok; M Gyldmark 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB

PCN87 A COST-EFFECTIVENESS ANALYSIS OF B

✍ HG Bischoff; D Heigener; C Wiesner; S Walzer 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

OP78 EGFR mutations based on circulating

✍ N. Yamamoto; Y. Ichinose; Y. Nishiwaki; Y. Ohe; K. Nishio; H. Jiang; E. Duffield 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 40 KB